Vaso-Occlusion in sickle cell disease: Pathophysiology and novel targeted therapies

Deepa Manwani, Paul S. Frenette

Research output: Contribution to journalReview articlepeer-review

240 Scopus citations


Recurrent and unpredictable episodes of vaso-occlusion are the hallmark of sickle cell disease. Symptomatic management and prevention of these events using the fetal hemoglobin-reactivating agent hydroxyurea are currently the mainstay of treatment. Discoveries over the past 2 decades have highlighted the important contributions of various cellular and soluble participants in the vaso-occlusive cascade. The role of these elements and the opportunities for therapeutic intervention are summarized in this review. (Blood. 2013;122(24):3892-3898).

Original languageEnglish (US)
Pages (from-to)3892-3898
Number of pages7
Issue number24
StatePublished - Dec 5 2013
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Vaso-Occlusion in sickle cell disease: Pathophysiology and novel targeted therapies'. Together they form a unique fingerprint.

Cite this